niacinamide has been researched along with Myelodysplastic Syndromes in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation." | 5.15 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011) |
| "Sorafenib is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)." | 2.78 | A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. ( Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W, 2013) |
| "Sorafenib is a small molecule inhibitor of RAF kinase, VEGFR-2, c-KIT, and FLT3." | 2.75 | A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. ( Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R, 2010) |
| "We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al." | 2.72 | Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. ( Chow, S; Hedley, D; Tong, FK, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadmor, T | 1 |
| Tallman, MS | 1 |
| Polliack, A | 1 |
| Crump, M | 1 |
| Hedley, D | 2 |
| Kamel-Reid, S | 2 |
| Leber, B | 2 |
| Wells, R | 1 |
| Brandwein, J | 2 |
| Buckstein, R | 1 |
| Kassis, J | 1 |
| Minden, M | 1 |
| Matthews, J | 1 |
| Robinson, S | 1 |
| Turner, R | 1 |
| McIntosh, L | 1 |
| Eisenhauer, E | 1 |
| Seymour, L | 1 |
| Borthakur, G | 1 |
| Kantarjian, H | 1 |
| Ravandi, F | 1 |
| Zhang, W | 1 |
| Konopleva, M | 1 |
| Wright, JJ | 1 |
| Faderl, S | 1 |
| Verstovsek, S | 1 |
| Mathews, S | 1 |
| Andreeff, M | 1 |
| Cortes, JE | 1 |
| Liesveld, JL | 1 |
| Rosell, KE | 1 |
| Bechelli, J | 1 |
| Lu, C | 1 |
| Messina, P | 1 |
| Mulford, D | 1 |
| Ifthikharuddin, JJ | 1 |
| Jordan, CT | 1 |
| Phillips Ii, GL | 1 |
| Wei, A | 1 |
| Tan, P | 1 |
| Macdonald, DA | 1 |
| Assouline, SE | 1 |
| Eisenhauer, EA | 1 |
| Couban, S | 1 |
| Caplan, S | 1 |
| Foo, A | 1 |
| Walsh, W | 1 |
| Tong, FK | 1 |
| Chow, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646] | Phase 1 | 36 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase II Pilot Study of VELCADE in Patients With MDS[NCT00262873] | Phase 2 | 8 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114] | Phase 2 | 57 participants (Actual) | Interventional | 2013-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00262873)
Timeframe: For 21 days/course for up to 12 courses
| Intervention | participants (Number) |
|---|---|
| Bortezomib | 6 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 16.1 | 28.6 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 14.75 | 14.75 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 27.65 | 54.28 |
The CD34+ fraction of light density marrow obtained from patients at baseline and while receiving bortezomib were assessed through measurement of Annexin V (assay obtained form R&D Systems) and by flow cytometry analysis. (NCT00262873)
Timeframe: day 14
| Intervention | percentage of apoptotic cells (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 6.68 | 11.37 |
"interleukin-6 levels were measured by enzyme-linked immunosorbant assay ELISA in serum from participants exposed to bortezomib.~Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial." (NCT00262873)
Timeframe: day 14
| Intervention | pg/ml (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 6.8 | 8.6 |
VEGF levels were measured by ELISA (R&DSystems) in serum from participants exposed to bortezomib. Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial. (NCT00262873)
Timeframe: day 14
| Intervention | pg/ml (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 402 | 254 |
5 trials available for niacinamide and Myelodysplastic Syndromes
2 other studies available for niacinamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Sorafenib - a small molecule with big promise?
Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relation | 2010 |
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea C | 2013 |